These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27914292)

  • 1. Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Lepow L; Luckenbaugh DA; Park L; Henter ID; Zarate CA
    J Psychiatr Res; 2017 Mar; 86():55-57. PubMed ID: 27914292
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking NMDA receptor at rest: a possible alleviation of depression.
    Lu W
    Acta Pharmacol Sin; 2011 Sep; 32(9):1087-8. PubMed ID: 21804573
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
    J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant effects of ketamine in depressed patients.
    Berman RM; Cappiello A; Anand A; Oren DA; Heninger GR; Charney DS; Krystal JH
    Biol Psychiatry; 2000 Feb; 47(4):351-4. PubMed ID: 10686270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
    Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
    Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
    Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine and the potential role for rapid-acting antidepressant medications.
    Krystal JH
    Swiss Med Wkly; 2007 Apr; 137(15-16):215-6. PubMed ID: 17525875
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
    Vanle B; Olcott W; Jimenez J; Bashmi L; Danovitch I; IsHak WW
    Transl Psychiatry; 2018 Jun; 8(1):117. PubMed ID: 29907742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.
    Hashimoto K
    Psychopharmacology (Berl); 2014 Oct; 231(20):4081-2. PubMed ID: 25189793
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
    DiazGranados N; Ibrahim LA; Brutsche NE; Ameli R; Henter ID; Luckenbaugh DA; Machado-Vieira R; Zarate CA
    J Clin Psychiatry; 2010 Dec; 71(12):1605-11. PubMed ID: 20673547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ketamine in treatment-refractory obsessive-compulsive disorder.
    Bloch MH; Wasylink S; Landeros-Weisenberger A; Panza KE; Billingslea E; Leckman JF; Krystal JH; Bhagwagar Z; Sanacora G; Pittenger C
    Biol Psychiatry; 2012 Dec; 72(11):964-70. PubMed ID: 22784486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial.
    Bevilacqua L; Charney A; Pierce CR; Richards SM; Jha MK; Glasgow A; Brallier J; Kirkwood K; Bagiella E; Charney DS; Murrough JW
    J Psychopharmacol; 2021 Feb; 35(2):124-127. PubMed ID: 33522376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.